Led · Series A · Feb 2026

Cambridge-based KluraLabs is a sustainable packaging company whose proprietary stickers and films slow the spoilage of fresh produce and baked goods without altering taste, odour, texture or appearance. The technology is designed to fit seamlessly into existing food packaging, improving logistics and reducing waste across the food-and-beverage supply chain. In retailer trials – including an early rollout with M&S – the solution has significantly extended the shelf life of berries, grapes and baked goods. Founded in 2020 by Matin Mohseni and Reza Saberi Moghaddam and led by CEO Charlie Hobhouse, the company sees its innovation as a way to save households and businesses money lost to food waste. The fresh capital will be used to scale manufacturing, broaden supermarket deployments and expand the R&D pipeline for additional freshness-preserving materials. KluraLabs’ longer-term goal is to revolutionise global food systems by embedding its freshness technology across multiple product categories. No revenue or user figures were disclosed in the article, but the business has now secured £7.7 million in total funding to date.

Led · Seed · Jan 2026

OutSee applies a “genomics-first” strategy to drug target discovery through its proprietary Nomaly platform, which employs hypothesis-free AI modelling to predict disease and phenotype directly from individual genomes. By analysing fundamental molecular and cellular biology, Nomaly is able to reveal disease-driving mechanisms even in small or previously analysed datasets, making it complementary to conventional target-discovery pipelines. The company is building an internal portfolio of data-backed targets and has already identified a lead candidate that will advance into drug discovery with support from external partners. A recent strategic collaboration with o2h discovery will create a library of drug candidates against this lead target, leveraging o2h’s integrated pre-clinical CRO capabilities and co-discovery InflexionTx match-funding model. Proceeds from OutSee’s oversubscribed £2.5 million seed round will fund experimental validation of additional targets, expansion of its in-house discovery programme, and continued R&D to evolve Nomaly from validation phase to active value generation. The financing also underscores growing investor confidence in the company’s AI-powered approach to precision medicine.

Participated · Series A · Dec 2025

Nu Quantum is pioneering distributed quantum computing by developing the Entanglement Fabric, a modular, interoperable photonic networking stack that links separate quantum processors into a single, more powerful system. Its approach targets the key industry hurdle of scaling qubit counts to reach fault-tolerant, utility-scale quantum computers. The firm has already demonstrated world-first subsystems such as a Qubit-Photon Interface slated for 2024 and a Quantum Networking Unit planned for 2025, and it is advancing research in Distributed Quantum Error Correction. Fresh capital will accelerate product development, expand its multidisciplinary team, and support international growth following the opening of a Los Angeles office and the formation of a U.S. strategic advisory board. Nu Quantum also convenes the Quantum Datacenter Alliance to foster ecosystem collaboration with quantum processing unit partners. The oversubscribed $60 million Series A— the largest pure-play quantum networking round globally and the largest quantum Series A in the UK—provides substantial runway for these ambitions.

Led · Seed · Nov 2025

Cassidy Bio is developing what it claims is the first AI-driven genomic foundation model that integrates proprietary wet-lab data, population-scale genomics and advanced machine learning to optimize the selection of guides, enzymes and delivery modalities for gene-editing therapeutics. By replacing today’s slow, trial-and-error approach with large-scale in-silico prediction and validation, the platform aims to increase precision, speed and clinical confidence in CRISPR-based drug development. The Tel Aviv-based startup’s end-to-end workflow ranks potential designs by safety and efficacy, with the goal of enabling reliable gene-editing medicines at scale rather than isolated successes. Its founding team combines serial biotech entrepreneur and CEO Rom Kshuk, CRISPR scientist Ayal Hendel, PhD, and AI specialist Yaniv Shmueli, PhD, and is supported by a scientific advisory board featuring former leaders from Editas Medicine, UPenn, Ultima Genomics and Intellia Therapeutics. Cassidy Bio plans to use newly raised capital to further train and validate its genomic foundation model and expand its wet-lab capabilities. To date, the company has secured $8 million in seed financing; no revenue, user or clinical metrics have yet been disclosed.

Participated · Seed · Sep 2025

Hiverge is a Cambridge-based company whose core product, the Hive platform, autonomously discovers algorithms that adapt to changing environments. The Hive has demonstrated more than 15% improvement over human-engineered methods on standard AI training benchmarks and delivered industrial planning algorithms for Airbus that run orders of magnitude faster than classical planners. By giving enterprises access to these automatically generated solutions, Hiverge aims to accelerate AI development and improve complex operational planning. With its recent capital injection, the company plans to scale go-to-market efforts, expand research capabilities, and enhance product development. Hiverge was founded by CEO Alhussein Fawzi, CTO Bernardino Romera-Paredes, and CSO Hamza Fawzi. The firm has not publicly disclosed revenue or user counts, but it has secured $5 million in seed financing to drive its next phase of growth.